<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01962896</url>
  </required_header>
  <id_info>
    <org_study_id>UTSW-GCT-001</org_study_id>
    <nct_id>NCT01962896</nct_id>
  </id_info>
  <brief_title>A Phase II Study of Sirolimus and Erlotinib in Recurrent/Refractory Germ Cell Tumors</brief_title>
  <official_title>A Phase II Study of Sirolimus and Erlotinib in Recurrent/Refractory Germ Cell Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Theodore Laetsch</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out if the combination of an mTOR inhibitor (sirolimus)&#xD;
      with an EGFR inhibitor (erlotinib) is effective at treating relapsed or refractory germ cell&#xD;
      tumors, and to find out what the side-effects of this regimen are.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Low accrual&#xD;
  </why_stopped>
  <start_date type="Actual">January 8, 2014</start_date>
  <completion_date type="Actual">January 27, 2018</completion_date>
  <primary_completion_date type="Actual">June 13, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The PFR, Defined as the Proportion of Patients With Refractory Germ Cell Tumors Free of Objective Disease Progression After 4 Cycles (16 Weeks) of Therapy With Erlotinib and Sirolimus</measure>
    <time_frame>16 weeks</time_frame>
    <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions: Progressive Disease (PD), &gt;= 20% increase in the sum of the longest diameter of target lesions or the development of any new lesions</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Toxicities of the Combination of Sirolimus and Erlotinib Administered on This Schedule.</measure>
    <time_frame>2 years</time_frame>
    <description>The number of patients with drug related grade III, IV, or V adverse events according to the Common Terminology Criteria for Adverse Events version 4.0.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Incidence of EGFR and mTOR Pathway Activation in Banked Tumor Specimens.</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Progression-free Interval (PFI) for Patients With Germ Cell Tumors With and Without Evidence of EGFR/mTOR Pathway Activation With This Drug Combination.</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Relapsed / Recurrent Germ Cell Tumors</condition>
  <arm_group>
    <arm_group_label>Erlotinib + sirolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erlotinib</intervention_name>
    <arm_group_label>Erlotinib + sirolimus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sirolimus</intervention_name>
    <arm_group_label>Erlotinib + sirolimus</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must be greater than 12 months and less than 50 years of age at the time of&#xD;
             study enrollment.&#xD;
&#xD;
          -  Patients must have had histologic verification of an extracranial germ cell tumor that&#xD;
             is not a pure mature teratoma.&#xD;
&#xD;
          -  Patients must have sufficient tumor tissue available to allow assessment of EGFR and&#xD;
             mTOR pathway activation (see Section 5.2.3 for sample requirements)&#xD;
&#xD;
          -  Patients must have relapsed or refractory disease following at least two prior&#xD;
             cisplatin containing chemotherapy regimens.&#xD;
&#xD;
          -  Patients must have measurable disease, documented according to RECIST criteria, or&#xD;
             evaluable disease with a standard tumor marker (AFP and/or HCG) greater than 10 times&#xD;
             the upper limit of normal.&#xD;
&#xD;
          -  Patients must have a Lansky or Karnofsky performance status score of ≥ 50. Use&#xD;
             Karnofsky for patients &gt; 16 years of age and Lansky for patients ≤ 16 years of age.&#xD;
&#xD;
          -  Patients must have a life expectancy of greater than 8 weeks.&#xD;
&#xD;
          -  Patients must have fully recovered from the acute toxic effects of all prior&#xD;
             anti-cancer therapy.&#xD;
&#xD;
               -  Patients must not have received myelosuppressive chemotherapy within 3 weeks of&#xD;
                  enrollment.&#xD;
&#xD;
               -  Patients must be &gt; 7 days since treatment with hematopoetic growth factors (&gt;14&#xD;
                  days for Neulasta).&#xD;
&#xD;
               -  Patients must be &gt;7 days since therapy with a biologic agent and beyond the&#xD;
                  period for which adverse events of the biologic agent are known to occur if&#xD;
                  longer.&#xD;
&#xD;
               -  Patients must be &gt;3 half-lives since therapy with a monoclonal antibody.&#xD;
&#xD;
               -  Patients must be &gt;42 days since completion of any immunotherapy (i.e. tumor&#xD;
                  vaccines).&#xD;
&#xD;
               -  Patients must be greater than 2 weeks since most recent palliative XRT and&#xD;
                  greater than 6 weeks since substantial bone marrow irradiation.&#xD;
&#xD;
               -  Patients must be greater than 8 weeks since prior stem cell transplant or&#xD;
                  infusion and without evidence of active graft vs. host disease.&#xD;
&#xD;
          -  Adequate bone marrow function defined as:&#xD;
&#xD;
               -  Peripheral absolute neutrophil count (ANC) of at least 1,000/ L&#xD;
&#xD;
               -  Platelet count of at least 100,000/ L (transfusion independent, defined as not&#xD;
                  receiving platelet transfusions within a 7-day period prior to enrollment)&#xD;
&#xD;
               -  Hemoglobin 8.0 g/dL (may receive RBC transfusions).&#xD;
&#xD;
          -  Adequate renal function defined as:&#xD;
&#xD;
               -  Creatinine clearance or radioisotope GFR 70 mL/min/1.73 m2 or&#xD;
&#xD;
               -  Maximum serum creatinine (mg/dL) based on age/gender&#xD;
&#xD;
          -  Adequate liver function defined as:&#xD;
&#xD;
               -  Total bilirubin ≤ 1.5 x upper limit of normal (ULN) for age&#xD;
&#xD;
               -  SGPT (ALT) ≤ 2.5 x ULN (for the purpose of this study, the ULN for SGPT is 45&#xD;
                  U/L)&#xD;
&#xD;
               -  Serum albumin ≥ 2 g/dL.&#xD;
&#xD;
          -  Adequate central nervous system function defined as:&#xD;
&#xD;
             o Patients with seizure disorder may be enrolled if receiving non-enzyme inducing&#xD;
             anticonvulsants and well controlled.&#xD;
&#xD;
          -  Serum cholesterol levels must be less than Grade 2 (&lt; 300 mg/dL), and serum&#xD;
             triglyceride levels must be less than Grade 2 (&lt; 2.5 x ULN).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with active brain metastases are not eligible as lethal intratumoral&#xD;
             hemorrhages have been reported with erlotinib therapy. Patients with brain metastases&#xD;
             that have been treated and stable for &gt; 30 days following treatment will be eligible.&#xD;
&#xD;
          -  Patients who are pregnant or breast feeding will not be entered into the study as&#xD;
             erlotinib is teratogenic. Pregnancy tests must be obtained in females who are&#xD;
             post-menarchal. Post-menarchal females with HCG secreting tumors will be excluded as&#xD;
             pregnancy can't be excluded. Males or females of reproductive potential may not&#xD;
             participate unless they have agreed to use an effective contraceptive method for the&#xD;
             duration of the study.&#xD;
&#xD;
          -  Concomitant medications&#xD;
&#xD;
               -  Investigational Drugs: Patients who are currently receiving another&#xD;
                  investigational drug are not eligible.&#xD;
&#xD;
               -  Anti-cancer Agents: Patients who are currently receiving other anti-cancer agents&#xD;
                  are not eligible.&#xD;
&#xD;
               -  Anticonvulsants: Patients who are receiving enzyme-inducing anticonvulsants are&#xD;
                  not eligible (see Appendix 1 for a list of enzyme- inducing anticonvulsants).&#xD;
&#xD;
               -  Anticoagulants: Use of warfarin is not allowed while on study. Patients already&#xD;
                  on warfarin should use alternative anticoagulants while on this study. Warfarin&#xD;
                  must not have been administered within 7 days of enrollment.&#xD;
&#xD;
               -  Smoking: Smoking induces CYP3A4/5 enzymes and decreases exposure to sirolimus and&#xD;
                  erlotinib. Thus, patients must not smoke for 10 days prior to enrollment and for&#xD;
                  the duration of therapy.&#xD;
&#xD;
          -  Infection: Patients who have an uncontrolled infection are not eligible.&#xD;
&#xD;
          -  Drug interactions: Sirolimus and erlotinib are primarily metabolized by the CYP3A4/5&#xD;
             enzymes. Drug exposure is substantially effected by CYP inhibitors (increased&#xD;
             exposure) and inducers (decreased exposure). Thus, concomitant administration of&#xD;
             strong CYP3A4/5 inhibitors or inducers is prohibited while on therapy. See Appendix 1&#xD;
             for a list of these medications. Patients must not have received these medications for&#xD;
             a minimum of 10 days prior to enrollment.&#xD;
&#xD;
          -  Patients who have received prior therapy targeting EGFR with small molecule tyrosine&#xD;
             kinase inhibitors or monoclonal antibodies are NOT eligible.&#xD;
&#xD;
          -  Prior treatment with mTOR or TORC1/2 inhibitors (eg, rapamycin, temsirolimus,&#xD;
             everolimus, sirolimus) is NOT allowed.&#xD;
&#xD;
          -  Patients who have had major surgery within 3 weeks prior to enrollment are not&#xD;
             eligible. Procedures such as placement of a central vascular catheter, or limited&#xD;
             tumor biopsy, are not considered major surgery.&#xD;
&#xD;
          -  Patients who in the opinion of the investigator may not be able to comply with the&#xD;
             safety monitoring requirements of the study are not eligible.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Months</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Jude Children's Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UT Southwestern Medical Center/Children's Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>September 20, 2013</study_first_submitted>
  <study_first_submitted_qc>October 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 14, 2013</study_first_posted>
  <results_first_submitted>January 11, 2019</results_first_submitted>
  <results_first_submitted_qc>February 5, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">February 26, 2019</results_first_posted>
  <last_update_submitted>February 5, 2019</last_update_submitted>
  <last_update_submitted_qc>February 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Texas Southwestern Medical Center</investigator_affiliation>
    <investigator_full_name>Theodore Laetsch</investigator_full_name>
    <investigator_title>Assistant Professor of Pediatrics</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms, Germ Cell and Embryonal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 27, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/96/NCT01962896/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Erlotinib + Sirolimus</title>
          <description>Erlotinib 85 mg/m2, max of 150 mg, was administered orally once daily continuously. Intrapatient dose escalation and de-escalation rules provided in the protocol.&#xD;
Sirolimus was started at a dose of 1 mg/m2, maximum 2mg, orally once daily continuously. The dose of sirolimus was be adjusted at least weekly to obtain a goal trough level of 10-15ng/mL.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Erlotinib + Sirolimus</title>
          <description>Erlotinib&#xD;
Sirolimus</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The PFR, Defined as the Proportion of Patients With Refractory Germ Cell Tumors Free of Objective Disease Progression After 4 Cycles (16 Weeks) of Therapy With Erlotinib and Sirolimus</title>
        <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions: Progressive Disease (PD), &gt;= 20% increase in the sum of the longest diameter of target lesions or the development of any new lesions</description>
        <time_frame>16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Erlotinib + Sirolimus</title>
            <description>Erlotinib&#xD;
Sirolimus</description>
          </group>
        </group_list>
        <measure>
          <title>The PFR, Defined as the Proportion of Patients With Refractory Germ Cell Tumors Free of Objective Disease Progression After 4 Cycles (16 Weeks) of Therapy With Erlotinib and Sirolimus</title>
          <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions: Progressive Disease (PD), &gt;= 20% increase in the sum of the longest diameter of target lesions or the development of any new lesions</description>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Toxicities of the Combination of Sirolimus and Erlotinib Administered on This Schedule.</title>
        <description>The number of patients with drug related grade III, IV, or V adverse events according to the Common Terminology Criteria for Adverse Events version 4.0.</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Erlotinib + Sirolimus</title>
            <description>Erlotinib&#xD;
Sirolimus</description>
          </group>
        </group_list>
        <measure>
          <title>The Toxicities of the Combination of Sirolimus and Erlotinib Administered on This Schedule.</title>
          <description>The number of patients with drug related grade III, IV, or V adverse events according to the Common Terminology Criteria for Adverse Events version 4.0.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>CTCAE v4 grade 3 AE</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>CTCAE v4 grade 4 AE</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>CTCAE v4 grade 5 AE</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No CTCAE v4 Grade &gt;2 AE</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Incidence of EGFR and mTOR Pathway Activation in Banked Tumor Specimens.</title>
        <time_frame>3 years</time_frame>
        <population>Analysis was not performed as the study was terminated early without sufficient enrollment to analyze this objective.</population>
        <group_list>
          <group group_id="O1">
            <title>Erlotinib + Sirolimus</title>
            <description>Erlotinib 85 mg/m2, max of 150 mg, was administered orally once daily continuously. Intrapatient dose escalation and de-escalation rules provided in the protocol.&#xD;
Sirolimus was started at a dose of 1 mg/m2, maximum 2mg, orally once daily continuously. The dose of sirolimus was be adjusted at least weekly to obtain a goal trough level of 10-15ng/mL.</description>
          </group>
        </group_list>
        <measure>
          <title>The Incidence of EGFR and mTOR Pathway Activation in Banked Tumor Specimens.</title>
          <population>Analysis was not performed as the study was terminated early without sufficient enrollment to analyze this objective.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Progression-free Interval (PFI) for Patients With Germ Cell Tumors With and Without Evidence of EGFR/mTOR Pathway Activation With This Drug Combination.</title>
        <time_frame>3 years</time_frame>
        <population>Analysis was not performed as the study was terminated early without sufficient enrollment to analyze this objective.</population>
        <group_list>
          <group group_id="O1">
            <title>Erlotinib + Sirolimus</title>
            <description>Erlotinib 85 mg/m2, max of 150 mg, was administered orally once daily continuously. Intrapatient dose escalation and de-escalation rules provided in the protocol.&#xD;
Sirolimus was started at a dose of 1 mg/m2, maximum 2mg, orally once daily continuously. The dose of sirolimus was be adjusted at least weekly to obtain a goal trough level of 10-15ng/mL.</description>
          </group>
        </group_list>
        <measure>
          <title>The Progression-free Interval (PFI) for Patients With Germ Cell Tumors With and Without Evidence of EGFR/mTOR Pathway Activation With This Drug Combination.</title>
          <population>Analysis was not performed as the study was terminated early without sufficient enrollment to analyze this objective.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AEs were collected from enrollment until the patient came off study, up to 2 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Erlotinib + Sirolimus</title>
          <description>Erlotinib&#xD;
Sirolimus</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Mucositis oral</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferrase increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Theodore Laetsch, MD</name_or_title>
      <organization>University of Texas Southwestern Medical Center</organization>
      <phone>214-648-5475</phone>
      <email>ted.laetsch@utsouthwestern.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

